

Title: Arrhythmogenic Right Ventricular Cardiomyopathy *GeneReview* — Less Common Genetic Causes

Authors: McNally E, MacLeod H, Dellefave-Castillo L

Updated: May 2017

Note: The following information is provided by the authors listed above and has not been reviewed by *GeneReviews* staff.

CTNNA3

Gene structure. According to the NCBI Reference sequence *CTNNA3* contains 18 exons with an mRNA 2687 bp in length.

Pathogenic variants. van Hengel et al reported two probands with missense variants c.281T>A (p.Val94Asp) and c.2293_2295delTTG (p.del765Leu). Functional studies supported a role for these changes in abnormal function of the protein [van Hengel et al 2013].

Table 5. Selected Pathogenic *CTNNA3* Variants

DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
c.281T>A	p.Val94Asp	NM_013266.3 NP_037398.2
c.2293_2295delTTG	p.Leu766del	

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society (www.hgvs.org). See [Quick Reference](#) for an explanation of nomenclature.

Normal gene product. The *CTNNA3* [NP_037398.2](#) transcript encodes a 895 amino acid protein belonging to the vinculin/alpha catenin family, alphaT-catenin. The protein plays a role in cell-cell adhesion in muscle cells. The alphaT-catenin protein directly couples the adherens junction to the actin cytoskeleton within the intercalated discs [Wickline et al 2016].

Abnormal gene product. The p.Val94Asp pathogenic variant has been shown to alter alphaT-catenin dimerization potential to disrupt beta-catenin binding and cellular localization [Wickline et al 2016].

RYR2

Gene structure. The transcript variant [NM_001035.2](#) comprises 105 exons. For a detailed summary of gene and protein information, see [Table A](#), **Gene**.

Pathogenic variants. Multiple pathogenic variants have been identified in *RYR2* that confer a phenotype more consistent with ARVC and phenotypically different from CPVT [Roux-Buisson et al 2014]. These variants differ from those found in *RYR2* in [CPVT](#) (see Table 2).

Normal gene product. *RYR2* encodes a 4967-amino acid protein ([NP_001026.2](#)) that is a 565-kd monomer. The ryanodine receptor 2 regulates calcium flux in the

intracellular space and mediates cardiac muscle excitation-contraction coupling [Tiso et al 2001, Roux-Buisson et al 2014].

Abnormal gene product. Pathogenic variants in *RYR2* are thought to result in an uncontrolled calcium leak in the cardiac myocyte, leading to arrhythmia.

TGFB3

Gene structure. The gene comprises seven exons. For a detailed summary of gene and protein information, see [Table A](#), **Gene**.

Pathogenic variants. Two pathogenic variants have been described, one in the 5' untranslated region of the gene and the second in the 3' untranslated region of the gene [Beffagna et al 2005].

Normal gene product. *TGFB3* encodes for transforming growth factor beta-3, which encodes for a cytokine-stimulating fibrosis and modulates cell adhesion.

Abnormal gene product. It is currently unknown how pathogenic variants in *TGFB3* cause ARVC.

References

Beffagna G, Occhi G, Nava A, Vitiello L, Ditadi A, Basso C, Baucé B, Carraro G, Thiene G, Towbin JA, Danieli GA, Rampazzo A. Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. *Cardiovasc Res* 2005;65:366-73.

Roux-Buisson N, Gandjbakhch E, Donal E, Probst V, Deharo JC, Chevalier P, Klug D, Mansencal N, Delacretaz E, Cosnay P, Scanu P, Extramiana F, Keller D, Hidden-Lucet F, Trapani J, Fouret P, Frank R, Fressart V, Faure J, Lunardi J, Charron P. Prevalence and significance of rare *RYR2* variants in arrhythmogenic right ventricular cardiomyopathy/dysplasia: results of a systematic screening. *Heart rhythm : the official journal of the Heart Rhythm Society*. 2014;11:1999-2009.

Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F, Larderet G, Brahmabhatt B, Brown K, Baucé B, Muriago M, Basso C, Thiene G, Danieli GA, Rampazzo A. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). *Hum Mol Genet* 2001;10:189-94.

van Hengel, J, Calore M, Baucé B, Dazzo E, Mazzotti E, De Bortoli M, Lorenzon A, Li Mura IE, Beffagna G, Rigato I, Vleeschouwers M, Tyberghein K, Hulpiau P, van Hamme E, Zaglia T, Corrado D, Basso C, Thiene G, Daliento L, Nava A, van Roy F, Rampazzo A. Mutations in the area composita protein alphaT-catenin are associated with arrhythmogenic right ventricular cardiomyopathy. *Eur Heart J*. 2013;34:201-10.

Wickline ED, Dale IW, Merkel CD, Heier JA, Stolz DB, Kwiatkowski AV. α T-catenin is a constitutive actin-binding alpha-catenin that directly couples the cadherin-catenin complex to actin filaments. *J Biol Chem*. 2016;291:15687-99.